RxDoctor Payments Data

Marcos Daccarett, MD

Clinical Cardiac Electrophysiology · Boise, IDNPI 1023144300

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $113,063 of the $154,066 with a category attached, or 73.4%. Boston Scientific accounts for 96.8% of it on its own, with 10 other manufacturers making up the rest. 2025 is the largest year on record at $64,174, 7.2 times the $8,852 reported in 2019.

$154,066in general payments, 2019–2025

Across 697 payments — averaging $221.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$149K
  • Abbott$2K
  • Biosense Webster, Inc.$1K
  • ZOLL Respicardia, Inc.$1K
  • Medtronic$135
  • Johnson & Johnson$130
  • plus $304 from 5 others
$369,656in research payments, 2019–2025

Across 132 payments — averaging $2800.43 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Boston Scientific$370K

What the payments were for

  • Consulting fees$13,3139%
  • Speaking & faculty fees$113,06373%
  • Travel & lodging$11,2717%
  • Food & beverage$16,42011%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few clinical cardiac electrophysiology providers in Idahoto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$365,987
Medicare patients
2,193
Services billed
4,460

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban437$467,351
XareltoRivaroxaban36$33,476
MultaqDronedarone Hcl11$14,305
Flecainide Acetate124$5,977
Dofetilide24$3,680
Mexiletine Hcl16$2,916
Amiodarone Hcl95$2,017
Metoprolol Succinate127$1,742
SotalolSotalol Hcl64$1,657
Digoxin81$1,509
ClopidogrelClopidogrel Bisulfate149$1,501
Diltiazem 24hr Er (Cd)Diltiazem Hcl60$1,473
Warfarin Sodium78$1,187
Diltiazem 24hr ErDiltiazem Hcl16$711
Metoprolol Tartrate61$558

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$130$33,47636 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few clinical cardiac electrophysiology providers in Idahoon file to place this against a meaningful peer group, so we don't.

Other clinical cardiac electrophysiology in Boise

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →